LeMaitre Vascular (LMAT) DIvidends Date & History

Key Takeaways

• LeMaitre Vascular pays a quarterly dividend of $0.25 per share, equating to an annualized dividend of $1.00 per share and a dividend yield of approximately 0.93%.
• The company has increased its dividend every year for 15 consecutive years, placing it among a select group of consistent dividend growers in the medical device sector.
• The payout ratio stands at roughly 34% of earnings and about 35% of free cash flow, indicating a highly sustainable dividend with ample room for future increases.
• In February 2026, the board approved a 25% dividend increase, reflecting management confidence in the company's financial trajectory.
• While the current yield is modest compared to income-oriented stocks, the combination of a low payout ratio and strong double-digit dividend growth makes LMAT attractive for dividend growth investors.

Dividend Overview

LeMaitre Vascular, Inc. (LMAT) is a specialized medical device company focused on devices, implants, and services for the treatment of peripheral vascular disease. The company pays a quarterly cash dividend, most recently set at $0.25 per share following a 25% increase announced in February 2026. At recent price levels, the annualized dividend of $1.00 per share translates to a dividend yield of roughly 0.93%. LeMaitre is best characterized as a dividend growth stock rather than a high-yield play. Its yield sits below the broader medical device industry median of approximately 1.87%, but the company more than compensates with an exceptional track record of annual dividend increases and a conservative payout structure that positions it for continued dividend expansion.

Dividend History and Growth

LeMaitre Vascular initiated its dividend program in 2011 and has raised its payout every year since, marking 15 consecutive years of dividend increases. The growth trajectory has been notable: the quarterly dividend has risen from $0.02 per share in 2011 to $0.25 per share as of early 2026. Over the past five years, the dividend has grown at a compound annual growth rate (CAGR) of roughly 13% to 17%, while the 10-year CAGR stands at approximately 17.1%. Recent increases underscore management's commitment to returning capital to shareholders. The dividend moved from $0.16 to $0.20 per quarter in early 2025, and then to $0.25 per quarter in early 2026 — a 25% year-over-year increase. Unlike many companies that freeze or cut dividends during uncertain periods, LeMaitre has maintained a steady cadence of quarterly increases throughout its dividend history, including during the COVID-19 pandemic.

Dividend Sustainability and Payout Ratio

LeMaitre Vascular's dividend is supported by a healthy and conservative financial foundation. The payout ratio based on trailing 12-month earnings is approximately 34%, while the free cash flow payout ratio sits around 35%. Both metrics are well below the 60% to 75% threshold that generally signals elevated risk for dividend cuts. In fiscal year 2025, the company generated $74.5 million in free cash flow and net income of $57.73 million, providing ample coverage for its dividend obligations. The company ended 2025 with $359 million in cash and securities and carries minimal debt, further reinforcing dividend safety. Gross margins of approximately 70% and operating margins in the mid-to-high 20% range provide a wide cushion against earnings volatility. The board also authorized a new $100 million share repurchase program in early 2026, demonstrating that the company generates sufficient cash flow to simultaneously fund dividends, buybacks, and organic growth initiatives.

Dividend Compared to Industry Peers

Within the medical devices and instruments industry, LeMaitre Vascular's dividend yield of roughly 0.93% sits below the industry median of approximately 1.87%. Larger medical device peers offer varying dividend profiles. MDT (Medtronic) offers a yield above 2% with a multi-decade growth streak, while BSX (Boston Scientific) does not pay a regular dividend. EW (Edwards Lifesciences) and TFX (Teleflex) also do not pay dividends, making LeMaitre something of an outlier among mid-cap medical device companies for its commitment to returning cash to shareholders. Where LeMaitre stands out is in dividend growth: its double-digit annual increases far outpace most dividend-paying peers in the healthcare sector. For investors willing to accept a lower starting yield in exchange for rapid dividend growth, LeMaitre presents a differentiated proposition within the medical device landscape.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery platform designed to help traders and investors efficiently filter thousands of equities using a broad range of customizable criteria. Users can scan for stocks based on technical indicators, fundamental metrics, volatility profiles, price patterns, and AI-driven trading signals. The screener allows for filtering by industry, market capitalization, dividend yield, and performance trends, making it a practical tool for identifying dividend stocks, income-focused investments, breakout candidates, and emerging market opportunities. By automating what would otherwise be hours of manual research, the AI Screener helps investors surface relevant investment ideas faster and with greater precision. Explore how the AI Screener can enhance your market research workflow today.

Is This Stock Attractive for Dividend Investors?

LeMaitre Vascular is best suited for dividend growth investors and long-term-oriented investors who prioritize consistent payout increases over high current income. The sub-1% yield is unlikely to satisfy investors seeking immediate income, such as retirees relying on portfolio distributions. However, for investors with a multi-year time horizon, the combination of a low payout ratio, robust free cash flow generation, and a 15-year streak of annual dividend increases offers a compelling case. The company's niche leadership in peripheral vascular surgery devices, high gross margins above 70%, strong balance sheet, and disciplined capital allocation suggest that the dividend growth trajectory can continue. The recent acceleration in dividend increases — including the 25% hike in early 2026 — signals management's growing confidence. For dividend-focused investors who are comfortable with a modest starting yield and are seeking above-average dividend growth within the healthcare sector, LeMaitre Vascular warrants consideration as part of a diversified dividend growth portfolio.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations